Cargando…

Comparison of Therapeutic Effect of Recombinant Tissue Plasminogen Activator by Treatment Time after Onset of Acute Ischemic Stroke

We aimed to compare the therapeutic effect of recombinant tissue plasminogen activator (rt-PA) administered at different time windows within the first 6 hours after onset of acute ischemic stroke (AIS). A retrospective analysis was performed of data collected from 194 patients who received rt-PA thr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Hai-rong, Chen, Miao, Wang, Fei-long, Dai, Li-hua, Fei, Ai-hua, Liu, Jia-fu, Li, Hao-jun, Shen, Sa, Liu, Ming, Pan, Shu-ming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4513278/ https://www.ncbi.nlm.nih.gov/pubmed/26206308 http://dx.doi.org/10.1038/srep11743

Ejemplares similares

Therapeutic effect of recombinant tissue plasminogen activator on acute cerebral infarction at different times
por: Liu, Ming, et al.
Publicado: (2013)

Quantitatively monitoring acute ischemic stroke patients post recombinant tissue plasminogen activator treatment
por: Liu, Yonge, et al.
Publicado: (2020)

A Canine Model of Hemorrhagic Transformation Using Recombinant Tissue Plasminogen Activator Administration After Acute Ischemic Stroke
por: Jiang, Run-Hao, et al.
Publicado: (2019)

Risk Factors Associated with Outcomes of Recombinant Tissue Plasminogen Activator Therapy in Patients with Acute Ischemic Stroke
por: Tseng, Yi-Ju, et al.
Publicado: (2020)

Effect of glycated hemoglobin index and mean arterial pressure on acute ischemic stroke prognosis after intravenous thrombolysis with recombinant tissue plasminogen activator
por: Liu, Shi-Ying, et al.
Publicado: (2018)

Neutrophilic noncoding RNAs predict outcomes of acute ischemic stroke patients treated with recombinant tissue plasminogen activator
por: Han, Ziping, et al.
Publicado: (2022)

Isoquercetin activates the ERK1/2-Nrf2 pathway and protects against cerebral ischemia-reperfusion injury in vivo and in vitro
por: Chen, Miao, et al.
Publicado: (2017)

Intravenous recombinant tissue plasminogen activator for acute ischemic stroke: a feasibility and safety study
por: Sadeghi-Hokmabadi, Elyar, et al.
Publicado: (2016)

Recombinant tissue plasminogen activator (rTPA) management for first onset acute ischemic stroke with covid -19 and non-covid -19 patients
por: Khedr, Eman M, et al.
Publicado: (2023)

Age-specific Cost Effectiveness of Using Intravenous Recombinant Tissue Plasminogen Activator for Treating Acute Ischemic Stroke
por: Joo, Heesoo, et al.
Publicado: (2017)

The influence of dehydration on the prognosis of acute ischemic stroke for patients treated with tissue plasminogen activator
por: Wu, Fei-Fan, et al.
Publicado: (2017)

Cost-Effectiveness of Recombinant Tissue Plasminogen Activator in the Management of Acute Ischemic Stroke: A Systematic Review
por: Jung, Kee-Taig, et al.
Publicado: (2010)

Genome response to tissue plasminogen activator in experimental ischemic stroke
por: Jickling, Glen C, et al.
Publicado: (2010)

Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator for Ischemic Stroke Patients over 80 Years Old: The Fukuoka Stroke Registry
por: Matsuo, Ryu, et al.
Publicado: (2014)

Intravenous Recombinant Tissue Plasminogen Activator Thrombolysis in a Patient with Acute Ischemic Stroke Secondary to Aortic Dissection
por: Hong, Keun-Sik, et al.
Publicado: (2009)

Hyperacute thrombolysis with recombinant tissue plasminogen activator of acute ischemic stroke: Feasibility and effectivity from an Indian perspective
por: Sharma, S. R., et al.
Publicado: (2008)

Current perspectives on the use of intravenous recombinant tissue plasminogen activator (tPA) for treatment of acute ischemic stroke
por: Chapman, Sherita N, et al.
Publicado: (2014)

Neuroendocrinal, Neurodevelopmental, and Embryotoxic Effects of Recombinant Tissue Plasminogen Activator Treatment for Pregnant Women with Acute Ischemic Stroke
por: Steinberg, Anna, et al.
Publicado: (2016)

Does Intravenous Administration of Recombinant Tissue Plasminogen Activator for Ischemic Stroke can Cause Inferior Myocardial Infarction?
por: Almasi, Mostafa, et al.
Publicado: (2016)

Carotid Artery Stenting for Acute Ischemic Stroke Patients after Intravenous Recombinant Tissue Plasminogen Activator Treatment
por: Deguchi, Ichiro, et al.
Publicado: (2016)

Relationship between homocysteine level and prognosis of elderly patients with acute ischemic stroke treated by thrombolysis with recombinant tissue plasminogen activator
por: Li, Juan, et al.
Publicado: (2019)

A Retrospective Study of thrombolysis with 0.6 mg/kg Recombinant Tissue Plasminogen Activator (rt-PA) in Mild Stroke
por: Yang, Jie, et al.
Publicado: (2016)

Emergent Double-barrel Bypass Shortly after Intravenous Administration of Recombinant Tissue Plasminogen Activator for Acute Ischemic Stroke
por: Choi, Joon-Ho, et al.
Publicado: (2016)

The Development of Pulmonary Edema after Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke Patient; Neurogenic or Non-Neurogenic?
por: Alwahdy, Ahmad Sulaiman, et al.
Publicado: (2022)

The Utility of Automated ASPECTS in Acute Ischemic Stroke for Intravenous Recombinant Tissue Plasminogen Activator (IV-rtPA) Therapy
por: Shibata, Soichiro, et al.
Publicado: (2022)

Different Doses of Intravenous Tissue-Type Plasminogen Activator for Acute Ischemic Stroke: A Network Meta-Analysis
por: Li, Bing-Hu, et al.
Publicado: (2022)

QiShenYiQi Inhibits Tissue Plasminogen Activator–Induced Brain Edema and Hemorrhage after Ischemic Stroke in Mice
por: Ye, Yang, et al.
Publicado: (2022)

Neuroprotection by cattle encephalon glycoside and ignotin beyond the time window of thrombolysis in ischemic stroke
por: Zhong, Jun, et al.
Publicado: (2020)

The key target of neuroprotection after the onset of ischemic stroke: secretory pathway Ca(2+)-ATPase 1
por: Li, Li-hua, et al.
Publicado: (2015)

Left ventricular apical thrombus after systemic thrombolysis with recombinant tissue plasminogen activator in a patient with acute ischemic stroke
por: Doepp, Florian, et al.
Publicado: (2005)

Intravenous tissue plasminogen activator, ischemic stroke, and the risk of Kounis Syndrome
por: Kounis, Nicholas G., et al.
Publicado: (2011)

Tissue plasminogen activator and patients with acute ischemic stroke: The litigation landscape
por: Ganti, Latha, et al.
Publicado: (2022)

Taurine-Upregulated Gene 1 Attenuates Cerebral Angiogenesis following Ischemic Stroke in Rats
por: Li, Fei, et al.
Publicado: (2022)

Predictors of Outcome and Hemorrhage in Patients Undergoing Endovascular Therapy with Solitaire Stent for Acute Ischemic Stroke
por: Jiang, Shaowei, et al.
Publicado: (2015)

Integrated analysis of ischemic stroke datasets revealed sex and age difference in anti-stroke targets
por: Li, Wen-Xing, et al.
Publicado: (2016)

Bioconjugation of recombinant tissue plasminogen activator to magnetic nanocarriers for targeted thrombolysis
por: Yang, Hung-Wei, et al.
Publicado: (2012)

Efficacy and safety of intravenous recombinant tissue plasminogen activator in mild ischaemic stroke: a meta-analysis
por: You, Shoujiang, et al.
Publicado: (2018)

Successful thrombolytic therapy with recombinant tissue plasminogen activator in ischemic stroke after idarucizumab administration for reversal of dabigatran: a case report
por: Ohtani, Toshiyuki, et al.
Publicado: (2019)

Outcome of stroke patients receiving different doses of recombinant tissue plasminogen activator
por: Ong, Cheung-Ter, et al.
Publicado: (2017)

Local Cerebral Recombinant Tissue Plasminogen Activator Concentrations During Acute Stroke
por: Essig, Fabian, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qs38rrg9jv41tebsch70qqmssr